carbamates has been researched along with Diabetic Angiopathies in 21 studies
Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with type 2 diabetes mellitus (T2DM), biomarkers reflecting inflammation and endothelial dysfunction have been linked to cardiovascular disease (CVD biomarkers) and metabolic regulation." | 2.73 | Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. ( Frandsen, M; Gram, J; Lund, SS; Parving, HH; Pedersen, O; Schalkwijk, CG; Smidt, UM; Stehouwer, CD; Tarnow, L; Teerlink, T; Vaag, AA; Winther, K, 2008) |
| "Glimepiride was associated with the best clinical outcome, showing the lowest mortality and lowest cardiovascular event risk of the five insulin secretagogues." | 1.51 | Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis. ( Huang, HK; Yeh, JI, 2019) |
| "In older patients with type 2 diabetes hospitalized for IHD, prior use of gliclazide, glyburide, or repaglinide appears to be associated with a similar risk of adverse cardiovascular sequelae." | 1.42 | Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study. ( Abdelmoneim, AS; Huang, Y; Light, P; Qiu, W; Simpson, SH, 2015) |
| "Type 2 diabetes mellitus is the consequence of both insulin resistance and impaired insulin secretion." | 1.32 | Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context. ( Abrahamson, MJ, 2004) |
| "The natural history of type 2 diabetes involves a progressive pancreatic beta-cell dysfunction leading to quantitative, qualitative and/or temporal abnormalities in insulin secretion and insensitivity to insulin action which predominates in muscles." | 1.30 | [Insulin secretion and repaglinide]. ( Owens, D, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (47.62) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 5 (23.81) | 29.6817 |
| 2010's | 5 (23.81) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, HK | 1 |
| Yeh, JI | 1 |
| Feng, L | 1 |
| Zhu, M | 1 |
| Zhang, M | 1 |
| Gu, J | 1 |
| Jia, X | 1 |
| Tan, X | 1 |
| Gao, C | 1 |
| Zhu, Q | 1 |
| Huang, Y | 1 |
| Abdelmoneim, AS | 1 |
| Light, P | 1 |
| Qiu, W | 1 |
| Simpson, SH | 1 |
| Ferrannini, E | 1 |
| DeFronzo, RA | 1 |
| Jarnert, C | 1 |
| Kalani, M | 1 |
| Rydén, L | 1 |
| Böhm, F | 1 |
| SANCHETTI, P | 1 |
| FAVERO, S | 1 |
| Abrahamson, MJ | 1 |
| Manzella, D | 1 |
| Grella, R | 2 |
| Abbatecola, AM | 1 |
| Paolisso, G | 2 |
| Rizzo, MR | 1 |
| Barbieri, M | 1 |
| Passariello, N | 1 |
| Lund, SS | 1 |
| Tarnow, L | 1 |
| Stehouwer, CD | 1 |
| Schalkwijk, CG | 1 |
| Teerlink, T | 1 |
| Gram, J | 1 |
| Winther, K | 1 |
| Frandsen, M | 1 |
| Smidt, UM | 1 |
| Pedersen, O | 1 |
| Parving, HH | 1 |
| Vaag, AA | 1 |
| Owens, D | 1 |
| Calvo Romero, JM | 1 |
| Lima Rodríguez, EM | 1 |
| Indovina, I | 1 |
| Furitano, G | 2 |
| Notarbartolo, A | 2 |
| Citarrella, P | 1 |
| Scaffidi, A | 1 |
| Girolami, A | 1 |
| Peruffo, R | 1 |
| Emanueli, A | 1 |
| Le Devehat, C | 1 |
| Lemoine, A | 1 |
| Parodi, FA | 1 |
| Caputo, G | 1 |
| Cajozzo, A | 1 |
| Spesivtseva, VG | 1 |
| Frenkel', VKh | 1 |
| Mamaeva, GG | 1 |
| Sokolovskiĭ, GA | 1 |
| Kukes, VG | 1 |
| Tirkina, TN | 1 |
| Aleksandrova, LM | 1 |
| Kliachko, VR | 1 |
| Mazovetskiĭ, AG | 1 |
| Plauchu, M | 1 |
| Bussy, L | 1 |
| Rondelet, J | 1 |
3 reviews available for carbamates and Diabetic Angiopathies
| Article | Year |
|---|---|
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
Topics: Carbamates; Clinical Trials as Topic; Coronary Artery Disease; Cyclohexanes; Diabetes Mellitus, Type | 2015 |
[Objectives and therapeutic strategy in type 2 diabetes mellitus].
Topics: Carbamates; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperinsulinism; Hypoglycemic | 2001 |
[Contribution of angioxine to the vascular protection of the diabetic].
Topics: Animals; Carbamates; Cerebrovascular Disorders; Coronary Disease; Diabetic Angiopathies; Diabetic Re | 1976 |
4 trials available for carbamates and Diabetic Angiopathies
| Article | Year |
|---|---|
Strict glycaemic control improves skin microcirculation in patients with type 2 diabetes: a report from the Diabetes mellitus And Diastolic Dysfunction (DADD) study.
Topics: Administration, Oral; Aged; Biomarkers; Blood Glucose; Brachial Artery; Carbamates; Diabetes Mellitu | 2012 |
Repaglinide administration improves brachial reactivity in type 2 diabetic patients.
Topics: Aged; Blood Glucose; Brachial Artery; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Dia | 2005 |
Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study.
Topics: Aged; Aged, 80 and over; Area Under Curve; Blood Glucose; Carbamates; Cardiovascular Diseases; Cross | 2005 |
Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Body Weight; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabeti | 2008 |
14 other studies available for carbamates and Diabetic Angiopathies
| Article | Year |
|---|---|
Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis.
Topics: Aged; Carbamates; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angio | 2019 |
The protection of 4,4'-diphenylmethane-bis(methyl) carbamate from Cortex Mori on advanced glycation end product-induced endothelial dysfunction: via inhibiting AGE formation or blocking AGEs-RAGE axis?
Topics: Apoptosis; Carbamates; Chromatography, High Pressure Liquid; Diabetic Angiopathies; Drugs, Chinese H | 2013 |
Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study.
Topics: Aged; Aged, 80 and over; Alberta; Blue Cross Blue Shield Insurance Plans; Carbamates; Cardiovascular | 2015 |
[CLINICAL STUDY OF A NEW COMPLEX HYPOTENSIVE DRUG COMBINATION].
Topics: Antihypertensive Agents; Arteriosclerosis; Carbamates; Cerebrovascular Disorders; Coronary Disease; | 1963 |
Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context.
Topics: Antihypertensive Agents; Blood Glucose; Blood Glucose Self-Monitoring; Carbamates; Diabetes Mellitus | 2004 |
[Insulin secretion and repaglinide].
Topics: Carbamates; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diet, Diabetic; Exercise; Humans; Hypo | 1999 |
[Pyridinolcarbamate in diabetic angiopathies].
Topics: Animals; Arteries; Blood Coagulation; Bradykinin; Carbamates; Coronary Vessels; Diabetic Angiopathie | 1978 |
Modifications of platelet retention in patients treated with pyridinolcarbamate. A preliminary report.
Topics: Adult; Aged; Carbamates; Diabetic Angiopathies; Female; Humans; Male; Middle Aged; Platelet Aggregat | 1977 |
[Preliminary study of a work concerning the activity of pyridinol carbamate on diabetic angiopathy (study of the microcirculation)].
Topics: Carbamates; Diabetic Angiopathies; Humans; Microcirculation; Pyridinolcarbamate | 1977 |
[The pyridinolcarbamate-clofibrate combination in the treatment of vascular diseases in diabetics].
Topics: Adult; Aged; Carbamates; Clofibrate; Diabetic Angiopathies; Drug Combinations; Drug Evaluation; Fema | 1976 |
[The efficacy of pyridonolcarbamate in diabetic angiopathy].
Topics: Blood Circulation; Blood Coagulation; Carbamates; Diabetic Angiopathies; Glycoproteins; Humans; Lipi | 1975 |
[Evaluation of the effectiveness of anginine treatment of diabetic microangiopathies].
Topics: Adult; Aged; Carbamates; Diabetic Angiopathies; Drug Evaluation; Female; Follow-Up Studies; Glomerul | 1975 |
[Pyridinolcarbamate (anginin) in the treatment of diabetic angiopathies].
Topics: Adolescent; Adult; Aged; Carbamates; Diabetic Angiopathies; Diabetic Retinopathy; Drug Evaluation; E | 1974 |
[Study of pyridinolcarbamate in the treatment of diabetic angiopathies and atheromatous arteritis].
Topics: Adult; Aged; Arteriosclerosis; Arteritis; Carbamates; Diabetic Angiopathies; Diabetic Retinopathy; F | 1972 |